VACCept Survey
Research type
Research Study
Full title
Survey to explore the acceptability of vaccination and knowledge of HPV in women aged 30 to 45 years attending for cervical screening.
IRAS ID
224891
Contact name
Tony Hollingworth
Contact email
Sponsor organisation
Queen Mary University London
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
Some types of HPV (Human Papillomavirus), called high-risk, are the main cause of cancer of the cervix (cervical) but only if the HPV infection does not go away.
HPV types 16 and 18 are found in around 7 out of 10 cervical cancers. Vaccines that can stop you getting HPV16 and 18, and so protect you against cervical cancer, are in use across the world. A newer HPV vaccine also protects from extra HPV types found in around 9 out of 10 cervical cancers.
These vaccines are best given before you ever have sex. They may still work if you have had sex but not caught the HPV types in the vaccine. In the UK girls aged 12 and 13 years can have the vaccine in school. Older women cannot have the vaccine on the NHS at the moment.
Giving women aged 25 to 45 years the vaccine could stop some of them getting cervical cancer. We don’t know exactly how much cancer could be stopped because very few older women have had the vaccine in this country. We also do not know if women would want to have the vaccine. We plan to ask women about this in an online survey. The aim is to find out if UK women aged 30-45 having a smear test would have the vaccine if it was offered to them. We want to understand who would say ‘yes’ or ‘no’ to the vaccine. We also want to know what women know about HPV and how they find out about it. This survey has been written by a team of European researchers called the CoheaHr Consortium and will be given to women in 11 countries in Europe.
Women who complete the survey will remain anonymous. This means no one will know who they are.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
17/LO/1281
Date of REC Opinion
26 Jul 2017
REC opinion
Favourable Opinion